KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Gross Profit (2022 - 2025)

Historic Gross Profit for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to -$9.5 million.

  • Recursion Pharmaceuticals' Gross Profit fell 16792.83% to -$9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.8 million, marking a year-over-year decrease of 21278.71%. This contributed to the annual value of $13.6 million for FY2024, which is 58415.49% up from last year.
  • Recursion Pharmaceuticals' Gross Profit amounted to -$9.5 million in Q3 2025, which was down 16792.83% from -$938000.0 recorded in Q2 2025.
  • Recursion Pharmaceuticals' Gross Profit's 5-year high stood at $14.0 million during Q3 2024, with a 5-year trough of -$9.5 million in Q3 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' median Gross Profit value was $1.0 million (recorded in 2023), while the average stood at -$10526.3.
  • The largest annual percentage gain for Recursion Pharmaceuticals' Gross Profit in the last 5 years was 417063.95% (2024), contrasted with its biggest fall of 91663.37% (2024).
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Gross Profit stood at $2.5 million in 2021, then increased by 11.96% to $2.8 million in 2022, then crashed by 64.39% to $1.0 million in 2023, then plummeted by 916.63% to -$8.2 million in 2024, then dropped by 15.32% to -$9.5 million in 2025.
  • Its Gross Profit stands at -$9.5 million for Q3 2025, versus -$938000.0 for Q2 2025 and -$7.1 million for Q1 2025.